Skip to main content
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Commentary

Hyperpolarized 13C Magnetic Resonance Treatment Response Monitoring: A New Paradigm for Multiorgan Metabolic Assessment of Pharmacological Interventions?

  1. Christoffer Laustsen⇑
  1. MR Research Centre, Department of Clinical Medicine, Aarhus University, Aarhus, Denmark
  1. Corresponding author: Christoffer Laustsen, cl{at}clin.au.dk.
Diabetes 2016 Dec; 65(12): 3529-3531. https://doi.org/10.2337/dbi16-0055
PreviousNext
  • Article
  • Figures & Tables
  • Info & Metrics
  • PDF
Loading

Metformin is one of the most used hyperglycemic control therapeutics in patients with diabetes, although the exact mechanism of action is still not fully understood (1,2). Metformin is the preferred antihyperglycemic drug in patients with type 2 diabetes; its use in patients with type 1 diabetes is limited however (3,4). A potential serious side effect of metformin treatment is lactic acidosis, which has reduced the applicability in renal-impaired patients; however, this has been questioned recently (5,6). These together support further investigations of, first, the exact mechanism of action and, second, the noninvasive methods for monitoring the treatment, in particular the organ-specific modulations imposed by metformin and their complex interorgan interactions, which historically have been especially difficult to assess.

This is particularly true in diseases where several organs are simultaneously affected, such as the cardio-renal syndrome, where dysfunction of one organ affects the other and vice versa and where the use of pharmacological interventions in the treatment of one organ can have detrimental effects on the other and vice versa (7,8). Thus the understanding of the organ-specific phenotypic characteristics in diabetes and the therapy-induced alterations is essential in the development of new treatments.

In this issue of Diabetes, the study by Lewis et al. (9) demonstrates that a metformin-induced redox change and following redistribution of the lactate and pyruvate pools via lactate dehydrogenase (LDH), which reflect a shift in the cosubstrates [NAD+]:[NADH], products [lactate]:[pyruvate], LDH concentration, and/or activation or inhibition of LDH itself, are directly monitored both acutely and chronically, with similar reprogrammed metabolic patterns.

Interestingly, the study finds an organ-specific metabolic pattern with an increased lactate production in the liver compared with the heart and potentially more important an increased lactate production following acute infusion of metformin (45 min prior to the examination), which was sustained during the full chronic period of 4 weeks of oral metformin treatment.

The study indicates that metformin reduces the glucogenic pathway (increased lactate pool) and in turn that no aerobic alterations are observed. Thus in spite of the acute and chronic metformin treatment–induced metabolic shift, both the liver and heart maintain normal oxidative metabolism. The whole-cell [NAD+]:[NADH] do not reflect the altered redox state, whereas a tendency to redox alterations was seen in the mitochondrial [acetoacetate]:[β-hydroxybutyrate] in the liver, similar to what has previously been seen in liver (2). The major finding of Lewis et al. (9) is the [lactate]:[pyruvate] redox dependency on the [1-13C]pyruvate:[1-13C]lactate conversion is already present acutely, and thus it is very likely that this change will be indicative of the [lactate]:[pyruvate] redox at 4 weeks, allowing for prognostic determination of the response to metformin if the redox state is associated with the outcome of metformin treatment (Fig. 1).

Figure 1
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1

An altered redox state following acute and chronic metformin treatment is observable with hyperpolarized [1-13C]pyruvate MR, originating from an increased [lactate]:[pyruvate] in both the liver and heart (observable as [1-13C]lactate:[1-13C]pyruvate). Only the chronic metformin-treated liver showed an altered mitochondrial redox via the [acetoacetate]:[β-hydroxybutyrate]. ACAC, acetoacetate; β-HB, β-hydroxybutyrate.

A potential limitation in the translation of hyperpolarized MR to the clinic is that the metabolic conversion associated with hyperpolarized MR examinations are limited to apparent rate constant mapping, and several factors determine the accurate rate constant. This can be largely overcome by investigating the same patient several times, thus acting as his or her own control. This is particularly relevant in monitoring the effects of treatments and development of diseases over time (10).

The prognostic potential of using hyperpolarized MR to detect organ-specific metabolic fingerprints in relation to diseases, and in particular the acute response to therapeutic interventions, and coupling them to the outcome of chronic treatment is a tremendous opportunity for researchers and clinicians.

The recent successful translation of hyperpolarized [1-13C]pyruvate MR examinations in prostate cancer patients (11) has paved the way for the use in other patient groups (12–15), such as patient with diabetes. It is now time to investigate the potential for this novel tool to aid in the assessment of diabetes, associated complications, and the treatment of these.

The hyperpolarized 13C MRI methodology, dynamic nuclear polarization MRI, increases the signal of an injectable biomarker substrate, often [1-13C]pyruvate, more than 10,000 times (11–14). The inherent low signal originating from the in vivo pool of carbons (approximately 1% of all carbons are 13C) is almost MRI invisible, and thus the labeling in a specific molecular position with the nonradioactive isotope 13C in combination with the increased signal of the biomarker substrate (>10,000 times) enables the injection of the biomarker and subsequent monitoring of the dynamic distribution and following enzymatic fate of the substrate inside cells into its metabolic derivatives, such as [1-13C]lactate, [1-13C]alanine, and 13CO2/H13CO3− in real time.

This dynamic measurement of the metabolism of 13C-labeled substrates is inherently radiation free and is conveniently performed in combination with the standard MRI examination. A limiting factor is the decay of the signal, which limits the investigations to fast metabolic processes (currently less than 2 min). The use of hyperpolarized [1-13C]pyruvate MRI provides an opportunity to combine the flexibility and safety of MR-based imaging with an exceptional signal-to-noise ratio. Exploration of injectable 13C-labeled substances has only recently entered human trials (11).

Article Information

Acknowledgments. C.L. acknowledges support from Danish Research Council for Independent Research.

Duality of Interest. No potential conflicts of interest relevant to this article were reported.

Footnotes

  • See accompanying article, p. 3544.

  • © 2016 by the American Diabetes Association.
http://www.diabetesjournals.org/content/license

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.

References

  1. ↵
    1. UK Prospective Diabetes Study (UKPDS) Group
    . Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854–865pmid:9742977
    OpenUrlCrossRefPubMedWeb of Science
  2. ↵
    1. Madiraju AK,
    2. Erion DM,
    3. Rahimi Y, et al
    . Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature 2014;510:542–546pmid:24847880
    OpenUrlCrossRefPubMedWeb of Science
  3. ↵
    1. Meyer L,
    2. Bohme P,
    3. Delbachian I, et al
    . The benefits of metformin therapy during continuous subcutaneous insulin infusion treatment of type 1 diabetic patients. Diabetes Care 2002;25:2153–2158pmid:12453953
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. Faichney JD,
    2. Tate PW
    . Metformin in type 1 diabetes: is this a good or bad idea? Diabetes Care 2003;26:1655pmid:12716858
    OpenUrlFREE Full Text
  5. ↵
    1. Nye HJ,
    2. Herrington WG
    . Metformin: the safest hypoglycaemic agent in chronic kidney disease? Nephron Clin Pract 2011;118:c380–c383pmid:21325870
    OpenUrlCrossRefPubMedWeb of Science
  6. ↵
    1. Rocha A,
    2. Almeida M,
    3. Santos J,
    4. Carvalho A
    . Metformin in patients with chronic kidney disease: strengths and weaknesses. J Nephrol 2013;26:55–60pmid:22641582
    OpenUrlCrossRefPubMedWeb of Science
  7. ↵
    1. Anavekar NS,
    2. McMurray JJ,
    3. Velazquez EJ, et al
    . Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004;351:1285–1295pmid:15385655
    OpenUrlCrossRefPubMedWeb of Science
  8. ↵
    1. Bongartz LG,
    2. Braam B,
    3. Gaillard CA, et al
    . Target organ cross talk in cardiorenal syndrome: animal models. Am J Physiol Renal Physiol 2012;303:F1253–F1263pmid:22914779
    OpenUrlAbstract/FREE Full Text
  9. ↵
    Lewis AJM, Miller JJJ, McCallum C, et al. Assessment of metformin-induced changes in cardiac and hepatic redox state using hyperpolarized[1-13C]pyruvate. Diabetes 2016:65:3544–3551
  10. ↵
    1. Serrao EM,
    2. Kettunen MI,
    3. Rodrigues TB, et al
    . MRI with hyperpolarised [1-13C]pyruvate detects advanced pancreatic preneoplasia prior to invasive disease in a mouse model. Gut 2016;65:465–475pmid:26347531
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Nelson SJ,
    2. Kurhanewicz J,
    3. Vigneron DB, et al
    . Metabolic imaging of patients with prostate cancer using hyperpolarized [1-¹³C]pyruvate. Sci Transl Med 2013;5:198ra108pmid:23946197
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Kurhanewicz J,
    2. Vigneron DB,
    3. Brindle K, et al
    . Analysis of cancer metabolism by imaging hyperpolarized nuclei: prospects for translation to clinical research. Neoplasia 2011;13:81–97pmid:21403835
    OpenUrlCrossRefPubMedWeb of Science
    1. Tyler DJ,
    2. Neubauer S
    . Science to practice: hyperpolarized metabolic MR imaging--the light at the end of the tunnel for clinical (13)C MR spectroscopy? Radiology 2016;278:639–641pmid:26885730
    OpenUrlPubMed
  13. ↵
    1. Laustsen C
    . Hyperpolarized renal magnetic resonance imaging: potential and pitfalls. Front Physiol 2016;7:72pmid:26973539
    OpenUrlPubMed
  14. ↵
    1. Serrao EM,
    2. Brindle KM
    . Potential clinical roles for metabolic imaging with hyperpolarized [1-(13)C]pyruvate. Front Oncol 2016;6:59pmid:27014634
    OpenUrlPubMed
PreviousNext
Back to top
Diabetes: 65 (12)

In this Issue

December 2016, 65(12)
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by Author
  • Masthead (PDF)
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Hyperpolarized 13C Magnetic Resonance Treatment Response Monitoring: A New Paradigm for Multiorgan Metabolic Assessment of Pharmacological Interventions?
(Your Name) has forwarded a page to you from Diabetes
(Your Name) thought you would like to see this page from the Diabetes web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Hyperpolarized 13C Magnetic Resonance Treatment Response Monitoring: A New Paradigm for Multiorgan Metabolic Assessment of Pharmacological Interventions?
Christoffer Laustsen
Diabetes Dec 2016, 65 (12) 3529-3531; DOI: 10.2337/dbi16-0055

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

Hyperpolarized 13C Magnetic Resonance Treatment Response Monitoring: A New Paradigm for Multiorgan Metabolic Assessment of Pharmacological Interventions?
Christoffer Laustsen
Diabetes Dec 2016, 65 (12) 3529-3531; DOI: 10.2337/dbi16-0055
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Article Information
    • Footnotes
    • References
  • Figures & Tables
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Adipose Tissue Malfunction Drives Metabolic Dysfunction in Alström Syndrome
  • Staying Connected: Transcriptomics in the Search for Novel Diabetic Kidney Disease Treatments
  • Going in Early: Hypoxia as a Target for Kidney Disease Prevention in Diabetes?
Show more Commentaries

Similar Articles

Navigate

  • Current Issue
  • Online Ahead of Print
  • Scientific Sessions Abstracts
  • Collections
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes Care
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Print ISSN: 0012-1797, Online ISSN: 1939-327X.